Perception versus reality ?: Virtual crossmatch - How to overcome some of the technical and logistic limitations

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1886-1893

  Tambur, A R ^a   Ramon, D S ^a   Kaufman, D B ^a   Friedewald, J ^a   Luo, X ^a   Ho, B ^a   Skaro, A ^a   Caicedo, J ^a   Ladner, D ^a   Baker, T ^a   Fryer, J ^a   Gallon, L ^a   Miller, J ^a   Abecassis, M M ^a   Leventhal, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antibodies; Antibody mediated rejection; Crossmatching; HLA; Kidney transplantation

Indexed keywords

HLA ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HLA SYSTEM; HOSPITAL LABORATORY; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; ORGAN DONOR; PANCREAS TRANSPLANTATION; PERCEPTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

FLOW CYTOMETRY; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TISSUE DONORS; TRANSPLANTATION;

EID: 67650935056     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02724.x     Document Type: Article

References (43)

1. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003 75 : 43 49.
2. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005 66 : 989 997.
3. Cherikh WSBT, Nelson K, Land G, Leffell M, Nikaein A. Broader geographic sharing through accurate prediction of crossmatch results. AJT 2006; World Transplant Congress (Abstract) no. 868 360.
4. Cherikh W. Variability of PRA levels and reporting of unacceptable antigens among transplant centers. Report to the Histocompatibility Committee on January 26, 2006 of an analysis of OPTN/UNOS data
5. Ho EK, Vasilescu ER, Colovai AI et al. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Transpl Immunol 2008 20 : 61 67.
6. van den Berg-Loonen EM, Billen EV, Voorter CE et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008 85 : 1086 1090.
7. Zachary AA. Antibody monitoring: A solid approach to predicting clinical outcome. Transplantation 2008 86 : 768.
8. Available at : http://www.unos.org/SharedContentDocuments/CPRA- Professionals.pdf. In.
9. Zangwill SD, Ellis TM, Zlotocha J et al. The virtual crossmatch-a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006 10 : 38 41.
10. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007 7 : 626 632.
11. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008 85 : 1200 1204.
12. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006 82 : 1524 1528.
13. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant 2007 11 : 650 654.
14. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008 85 : 1046 1050.
15. Appel JZ, 3rd., Hartwig MG, Cantu E, 3rd., Palmer SM, Reinsmoen NL, Davis RD. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006 81 : 1049 1057.
16. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008 86 : 820 825.
17. Available at : http://www.asts.org/Tools/Download.aspx?fid=760. In.
18. Tambur AR, Leventhal J, Kaufman DB, Friedewald J, Miller J, Abecassis MM. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: The Northwestern University experience. Transplantation 2008 86 : 1052 1059.
19. Owens DL, Zavazava N, McChesney LP, Hunsicker LG, Field EH. A case of antibody mediated rejection from anti-donor HLA-Cw antibody. Hum Immunol 2008 69 (S1 S123 abstract).
20. Warner PR Youngs D, Nelson KA. Comparing the UNOS/OPTN CPRA system vs. local CPRA system. Hum Immunol 2008 69 (S1 S108 abstract).
21. Zoet YME, Witvliet MD, Kardol MJ, Claas FHJ, Mulder A, Doxiadis IIN. HLA-Cw specific antibodies and kidney transplantation. [Abstract] Transplantation 2004 78 (Suppl1 52: O 483.
22. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004 29 : 41 54.
23. Kerman RH, Susskind B, Buyse I et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999 68 : 1855 1858.
24. Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001 12 : 2807 2814.
25. Scornik JC, Clapp W, Patton PR et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001 71 : 1098 1102.
26. Cho YW, Cecka JM. Crossmatch tests-an analysis of UNOS data from 1991-2000. Clin Transpl 2001 : 237 246.
27. Higgins R, Hathaway M, Lowe D et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007 84 : 876 884.
28. Gebel HM, Harris SB, Zibari G, Bray RA. Conundrums with FlowPRA beads. Clin Transplant 2002 16 (Suppl 7 24 29.
29. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009 162 : 1 12.
30. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient. Semin Dial 2005 18 : 474 481.
31. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007 7 : 2371 2377.
32. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008 8 : 324 331.
33. Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M. Positive remote crossmatch: Impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003 75 : 501 505.
34. Gloor JM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004 78 : 221 227.
35. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 2004 78 : 1471 1478.
36. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001 1 : 260 269.
37. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001 108 : 943 948.
38. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006 6 : 1841 1847.
39. Haas M, Montgomery RA, Segev DL et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007 7 : 576 585.
40. Jin YP, Fishbein MC, Said JW et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004 65 : 291 302.
41. Jindra PT, Zhang X, Mulder A et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006 82 (Suppl 1 S33 S35.
42. Jindra PT, Hsueh A, Hong L et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008 180 : 2214 2224.
43. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003 3 : 1488 1500.